Startseite › Urothelkarzinom (Transitional Cell Carcinoma) › New York › New York City
Klinische Studien zu Urothelkarzinom (Transitional Cell Carcinoma) in New York City, NY
22 Studien zu Urothelkarzinom (Transitional Cell Carcinoma) suchen Teilnehmer an Standorten in und um New York City (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Teilnehmer gesuchtPhase 2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- NYP/Weill Cornell Medical Center, New York
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Teilnehmer gesuchtBeobachtungsstudie
- NYU Grossman School of Medicine, New York
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Teilnehmer gesuchtPhase 1/2
- Memorial Sloan Kettering Cancer Center ( Site 1031), New York
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Teilnehmer gesuchtPhase 1/2
- Icahn School of Medicine at Mount Sinai, New York
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Columbia University Irving Medical Center, New York
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Teilnehmer gesuchtPhase 3
- Columbia University Irving Medical Center, New York
- Memorial Sloan Kettering Cancer Center, New York
- Weill Cornell Medical College, New York
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy
Teilnehmer gesuchtPhase 1
- Mount Sinai Hospital, New York
- NYP/Weill Cornell Medical Center, New York
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer
Teilnehmer gesuchtPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Teilnehmer gesuchtPhase 1
- New York Cancer & Blood Specialists, New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Teilnehmer gesuchtPhase 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Centre (BAIC), New York
- und 2 weitere
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Teilnehmer gesuchtPhase 3
- Research Site, New York
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Teilnehmer gesuchtPhase 2
- Memorial Sloan Kettering Cancer Center, New York
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Teilnehmer gesucht
- Integrated Medical Professionals, New York
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Teilnehmer gesuchtPhase 1
- MSK, New York
A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma
Teilnehmer gesuchtBeobachtungsstudie
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Teilnehmer gesuchtPhase 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, New York
Urothelkarzinom (Transitional Cell Carcinoma)-Studien in anderen Städten
- Nashville, TN23 Studien
- Houston, TX19 Studien
- Dallas, TX18 Studien
- Edison, NJ18 Studien
- Los Angeles, CA17 Studien
- Queens, NY15 Studien
- Chicago, IL14 Studien
- Arlington, VA12 Studien
- Boston, MA11 Studien
- San Antonio, TX11 Studien
- Austin, TX10 Studien
- Orange, CA10 Studien
Weitere Studien in New York City
- Brustkrebs136 Studien
- Nichtkleinzelliges Lungenkarzinom121 Studien
- Krebs (alle Arten)109 Studien
- Prostatakrebs103 Studien
- Metastasierender Krebs93 Studien
- Kolorektales Karzinom78 Studien
- Eierstockkrebs69 Studien
- Lungenkrebs60 Studien
- Multiples Myelom60 Studien
- Bauchspeicheldrüsenkrebs60 Studien
- Endometriumkarzinom52 Studien
- Akute myeloische Leukämie51 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.